SERPING1 and hereditary angioedema: Accordingly, a phase III randomized clinical trial (NCT02586805) evaluated the efficacy and safety of lanadelumab to prevent HAE attacks in patients with symptomatic HAE due to C1 inhibitor deficiency (C1-INH-HAE) disorder (403).